SCHEMBL23054823

SCHEMBL23054823

CN(C)C(=O)CCCCCCCC(=O)Nc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 17/20 0.66
HDAC2 Q92769 17/20 0.66
HDAC1 Q13547 16/20 0.66
HDAC6 Q9UBN7 16/20 0.66
HDAC4 P56524 15/20 0.66
HDAC11 Q96DB2 15/20 0.66
HDAC5 Q9UQL6 15/20 0.66
HDAC3 O15379 15/20 0.66
HDAC7 Q8WUI4 14/20 0.66
HDAC9 Q9UKV0 14/20 0.66
HDAC10 Q969S8 14/20 0.66
NCOR1 O75376 2/20 0.66
KDM4E B2RXH2 1/20 0.66
BRD4 O60885 1/20 0.66
NR1I2 O75469 1/20 0.66
EGFR P00533 1/20 0.66
CYP3A4 P08684 1/20 0.66
LTA4H P09960 1/20 0.66
NR0B1 P51843 1/20 0.66
PLK1 P53350 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23054822 1.00 HDAC8 (0.66) HDAC8HDAC2HDAC1HDAC6HDAC4
SCHEMBL23054864 1.00 HDAC8 (0.66) HDAC8HDAC2HDAC1HDAC6HDAC4
SCHEMBL23055025 1.00 HDAC8 (0.66) HDAC8HDAC2HDAC1HDAC6HDAC4
SCHEMBL23054781 0.98 HDAC8 (0.63) HDAC8HDAC2HDAC1HDAC6HDAC4
SCHEMBL9452229 0.95 HDAC4 (0.58) HDAC8HDAC2HDAC1HDAC6HDAC4
SCHEMBL13709002 0.89 HDAC8 (0.64) HDAC8HDAC2HDAC1HDAC6HDAC4
SCHEMBL29275458 0.88 L3MBTL1 (0.61) HDAC8HDAC2HDAC1HDAC6HDAC4
SCHEMBL137348 0.86 HDAC4 (0.85) HDAC8HDAC2HDAC1HDAC6HDAC4
SCHEMBL6669511 0.86 HDAC4 (0.85) HDAC8HDAC2HDAC1HDAC6HDAC4
SCHEMBL1065393 0.86 HDAC4 (0.85) HDAC8HDAC2HDAC1HDAC6HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC8 4/4885HDAC2 3/4885HDAC1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.